Immunogen (IMGN)

ImmunoGen (IMGN) Stock Price & Analysis


IMGN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.10 - $6.63
Previous Close$3.93
Average Volume (3M)3.56M
Market Cap
Enterprise Value$628.47M
Total Cash (Recent Filing)$275.14M
Total Debt (Recent Filing)$15.24M
Price to Earnings (P/E)-4.5
May 05, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding220,750,928
10 Day Avg. Volume3,477,185
30 Day Avg. Volume3,561,171
Standard Deviation0.19
Financial Highlights & Ratios
Price to Book (P/B)5.18
Price to Sales (P/S)13.65
Price to Cash Flow (P/CF)141.00
P/FCF Ratio-5.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.78
Enterprise Value/Gross Profit5.79
Enterprise Value/Ebitda-2.91
Price Target Upside191.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Immunogen’s price range in the past 12 months?
Immunogen lowest stock price was $3.10 and its highest was $6.63 in the past 12 months.
    What is Immunogen’s market cap?
    Currently, no data Available
    When is Immunogen’s upcoming earnings report date?
    Immunogen’s upcoming earnings report date is May 05, 2023 which is in 44 days.
      How were Immunogen’s earnings last quarter?
      Immunogen released its earnings results on Mar 01, 2023. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.296 by $0.066.
        Is Immunogen overvalued?
        According to Wall Street analysts Immunogen’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Immunogen pay dividends?
          Immunogen does not currently pay dividends.
          What is Immunogen’s EPS estimate?
          Immunogen’s EPS estimate is -$0.25.
            How many shares outstanding does Immunogen have?
            Immunogen has 226,046,110 shares outstanding.
              What happened to Immunogen’s price movement after its last earnings report?
              Immunogen reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.296. Following the earnings report the stock price went up 3.608%.
                Which hedge fund is a major shareholder of Immunogen?
                Among the largest hedge funds holding Immunogen’s share is RA Capital Management. It holds Immunogen’s shares valued at 108M.


                  ImmunoGen Stock Smart Score

                  The ImmunoGen stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description


                  ImmunoGen, Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779 and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Zentalis Pharmaceuticals
                  TG Therapeutics
                  Madrigal Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis